Pharmacodynamics and common drug-drug interactions of the third-generation antiepileptic drugs

Potentially Clinically Relevant Pharmacodynamic Interactions Between Antiepileptic Drugs and Psychotropic Drugs: An Update

(2018) Edoardo Spina et al.   CURRENT PHARMACEUTICAL DESIGN

Antiepileptic potential of ganaxolone

(2017) Slobodan Jankovic et al.   Vojnosanitetski Pregled

Efficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis

(2017) Chuanjun Zhuo et al.   Scientific Reports

Antiepileptic Drugs Under Investigation for Treatment of Focal Epilepsy

(2016) Pasquale Striano et al.   CLINICAL NEUROPHARMACOLOGY

Pharmacokinetic/pharmacodynamic considerations for epilepsy – depression comorbidities

(2016) Monika Banach et al.   Expert Opinion on Drug Metabolism & Toxicology

Third generation antiepileptic drug monotherapies in adults with epilepsy

(2016) Marco Mula   Expert Review of Neurotherapeutics

The New Antiepileptic Drugs: Their Neuropharmacology and Clinical Indications

(2016) Ryosuke HANAYA et al.   NEUROLOGIA MEDICO-CHIRURGICA

The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice

(2016) Cecilie Johannessen Landmark et al.   THERAPEUTIC DRUG MONITORING

Therapeutic Drug Monitoring of Clobazam and Its Metabolite—Impact of Age and Comedication on Pharmacokinetic Variability

(2016) Margrete L. Burns et al.   THERAPEUTIC DRUG MONITORING

Third generation antiepileptic drug monotherapies in adults with epilepsy

(2016) Marco Mula   Expert Review of Neurotherapeutics

Brivaracetam and carbamazepine interaction in healthy subjects and in vitro

(2015) Armel Stockis et al.   EPILEPSY RESEARCH

Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: A comparison with carbamazepine, oxcarbazepine and lacosamide

(2015) Simon Hebeisen et al.   NEUROPHARMACOLOGY

Efectos de los inductores antiepilépticos en la neuropsicofarmacología: una cuestión ignorada. Parte I: Resumen para los clínicos de la situación actual

(2015) Jose de Leon   Revista de Psiquiatria y Salud Mental

Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug

(2014) Anna Doeser et al.   BRAIN

Eslicarbazepine Acetate: A Review of Its Use as Adjunctive Therapy in Refractory Partial-Onset Seizures

(2014) Gillian M. Keating   CNS DRUGS

Brivaracetam Differentially Affects Voltage-Gated Sodium Currents Without Impairing Sustained Repetitive Firing in Neurons

(2014) Isabelle Niespodziany et al.   CNS Neuroscience & Therapeutics

Perampanel Inhibition of AMPA Receptor Currents in Cultured Hippocampal Neurons

(2014) Chao-Yin Chen et al.   PLoS One

Pharmacodynamic and pharmacokinetic interactions of perampanel and other antiepileptic drugs in a rat amygdala kindling model

(2014) Ting Wu et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist

(2013) M. A. Rogawski et al.   ACTA NEUROLOGICA SCANDINAVICA

Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders

(2013) Philip N. Patsalos   CLINICAL PHARMACOKINETICS

Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 1: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs

(2013) Philip N. Patsalos   CLINICAL PHARMACOKINETICS

Issues for new antiepilepsy drug development

(2013) Michele Simonato et al.   CURRENT OPINION IN NEUROLOGY

Stiripentol in refractory status epilepticus

(2013) Denise K. Grosenbaugh et al.   EPILEPSIA

Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers

(2013) Willi Cawello et al.   EPILEPSIA

Clobazam Therapeutic Drug Monitoring

(2013) Jose de Leon et al.   THERAPEUTIC DRUG MONITORING

Lacosamide Therapeutic Monitoring in Patients With Epilepsy

(2013) Manuela Contin et al.   THERAPEUTIC DRUG MONITORING

New drug classes for the treatment of partial onset epilepsy: focus on perampanel

(2013) Jerry Shih et al.   Therapeutics and Clinical Risk Management

A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus

(2012) Laura Ceolin et al.   NEUROCHEMISTRY INTERNATIONAL

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties

(2011) Michel Gillard et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study

(2011) Manuel Vaz-Da-Silva et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A Pooled Analysis of Lacosamide Clinical Trial Data Grouped by Mechanism of Action of Concomitant Antiepileptic Drugs

(2010) John-Kenneth Sake et al.   CNS DRUGS

Antiepileptic Drug Interactions - Principles and Clinical Implications

(2010) Svein I. Johannessen et al.   Current Neuropharmacology

Lacosamide: new adjunctive treatment option for partial-onset seizures

(2010) Steve S Chung   EXPERT OPINION ON PHARMACOTHERAPY

Rufinamide: A Novel Broad-Spectrum Antiepileptic Drug

(2010) James W. Wheless et al.   Epilepsy Currents

Drug interactions involving the new second- and third-generation antiepileptic drugs

(2009) Cecilie Johannessen Landmark et al.   Expert Review of Neurotherapeutics

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A

(2008) A Matagne et al.   BRITISH JOURNAL OF PHARMACOLOGY

SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

(2007) Rafal M. Kaminski et al.   NEUROPHARMACOLOGY